RxDoctor Payments DataLook up a doctor →

Mohammad Samer Younes, MD

Family Medicine · Hartford, CTNPI 1114455987

Payments from drug & device makers

$19,500in general payments, 2019–2025

Across 998 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Pfizer$2K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • GSK$1K
  • plus $9K from 48 others

What the payments were for

  • Food & beverage$19,454100%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,500 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$55,751
Medicare patients
124
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$74,039
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$72,873
EliquisApixaban75$48,789
OzempicSemaglutide43$41,754
TrulicityDulaglutide22$29,644
JardianceEmpagliflozin16$26,319
Tresiba Flextouch U-200Insulin Degludec30$21,040
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$20,414
XareltoRivaroxaban22$17,001
MounjaroTirzepatide14$14,464
Repatha SureclickEvolocumab14$11,733
Breo ElliptaFluticasone/Vilanterol17$7,677
TrulancePlecanatide11$6,565
Rosuvastatin Calcium330$5,797
Omeprazole296$4,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,383$100,964130 claims
AmgenOtezla$1,429$74,03916 claims
PfizerEliquis$1,888$48,78975 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin N$1,232$46,13750 claims
Novo NordiskOzempic$1,635$41,75443 claims
Boehringer IngelheimJardiance$686$26,31916 claims
Johnson & JohnsonXarelto$1,080$17,00122 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$27$6,56511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →